Science and Technology Committee
10 March 2026
No chapters available yet
Legend
Transcript markers
- text Sentence being played
- text Search result
- text Intervention cited by the link you opened
Click a sentence to play the video from that moment. Select text to quote it with the speaker, timestamp and link.
More options
Science and Technology Committee House of Lords
00:03 - 01:29
Speaker 1
Welcome to this science and technology select committee. We are embarking on a new inquiry, innovation in the NHS, personalized medicine and AI, And we're very pleased to have as our first witness, professor Samarc Caulfield, who's the professor of clinical pharmacology at Queen Mary University of London. Samarc, by way of of an opening statement, please, by all means, introduce yourself, but perhaps you could give our committee an overview, in in simple terms of of what we mean by personalized personalized and genomic medicine, what its potential is, where it stands today in The UK, what are the major areas of application this committee should look in into? Further than that, to what extent are we able to use analysis of individual patient genomes to give them personalized care? What are some of the near term applications of genomic medicine that are the most promising?
Further, what can we do now for patients that we couldn't do when you started the 100,000 genomes project? And and what do you think might be possible within the next five to ten years? So there are some challenging questions.
01:29 - 03:12
Speaker 2
Over to you. Thank you very much. So as you've heard, I'm professor Samark Cauffelton. It's a real privilege to be here and share what I know about the 100,000 Genomes Project and other aspects of Genomics England and the status of precision medicine or personalised healthcare in The UK, but also in the global context too. So I'm currently Vice Principal for Health at Queen Mary and Director of the National Institute for Health Research, Bart's Biomedical Research Centre.
And as you've heard, I'm a consultant physician and clinical pharmacologist by training at Bart's Health. I'm also a non executive director on two NHS Trust boards, Bart's Health and Barking and Brin Redbridge, and I'm on the Council of the Medical Research Council and Research England's clinical medicine panel for the Research Excellence Framework. I also advise many countries, and I'm on the board of the Canadian Genomics Infrastructure Company, advising Canada on their sites in Montreal, Toronto, and Vancouver, and, many other countries across the world. But I'm here because between 2013, July 07/05/2013, which is the birthday of the NHS, and July 2021, I was seconded from Queen Mary to be chief scientist for Genomics England Limited, a wholly owned department of health company, where I was an executive board director, and I led strategy and delivery of the 100,000 Genomes Project, which worked predominantly in England initially, but also, because we want to include the entire UK, secured money from the Medical Research Council for Scotland, Northern Ireland, and Wales to be part of the project. So, chair, if I may move to the opening statement.
The rest of the transcript is for Pro customers
Unlock the full transcript, chat, and every analysis feature with Polyfact Pro.
The video itself stays free to watch, in full, no account needed.
Ask anything about this video — I analyse its transcript to answer.